Structural Insights from Molecular Modeling of Isoindolin-1-One Derivatives as PI3Kγ Inhibitors against Gastric

Suparna Ghosh1, Seung Joo Cho1,2

  • 1Department of Biomedical Sciences, College of Medicine, Chosun University, Gwangju 501-759, Korea.

Biomedicines
|April 23, 2022
PubMed

Insights

This study developed novel isoindolin-1-one derivatives as selective phosphoinositol-3-kinase gamma (PI3Kγ) inhibitors. Molecular modeling identified key differences between PI3Kγ and PI3Kδ, guiding the design of potent compounds for gastric carcinoma therapy.

Area of Science:

  • Medicinal Chemistry
  • Computational Chemistry
  • Oncology

Background:

  • Upregulation of phosphoinositol-3-kinase gamma (PI3Kγ) correlates with tumor-associated macrophage (TAM)-mediated gastric carcinoma (GC).
  • PI3Kγ promotes an immunosuppressant TAM phenotype by suppressing TNF-α and IL-12 via AKT/mTOR activation.
  • Selective PI3Kγ inhibitors are needed to target cancer, as PI3Kδ and PI3Kγ isoforms have distinct activation mechanisms and distributions.

Purpose of the Study:

  • To design and identify potent and selective PI3Kγ inhibitors using molecular modeling.
  • To elucidate the structural and physicochemical factors governing PI3Kγ selectivity over PI3Kδ.
  • To explore novel isoindolin-1-one derivatives as potential therapeutic agents for PI3Kγ-driven cancers.

Main Methods:

  • Employed molecular docking, molecular dynamics (MD), MM-PB/GBSA binding free energy calculations, and 3D-QSAR studies.
  • Investigated idelalisib analogs to understand PI3Kδ inhibition and compare binding modalities with PI3Kγ.
  • Utilized comparative molecular field analysis (CoMFA) and comparative molecular similarity index analysis (CoMSIA) to generate contour maps and analyze structure-activity relationships (SAR).

Main Results:

  • Identified key differences in binding sites and interactions between PI3Kγ and PI3δ isoforms.
  • Designed novel isoindolin-1-one derivatives with predicted high binding affinity and selectivity for PI3Kγ using a fragment-substitution strategy.
  • 3D-QSAR models successfully predicted inhibitory activity (pIC50) and MM-PB/GBSA confirmed binding energy for designed compounds.

Conclusions:

  • The developed molecular modeling approach effectively guided the design of selective PI3Kγ inhibitors.
  • The designed isoindolin-1-one derivatives show significant potential as targeted therapeutics for gastric carcinoma.
  • Understanding isoform-specific interactions is crucial for developing selective kinase inhibitors with improved efficacy and reduced side effects.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.0K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.1K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
275